Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.

Authors: Sakaguchi, H  Okuno, Y  Muramatsu, H  Yoshida, K  Shiraishi, Y  Takahashi, M  Kon, A  Sanada, M  Chiba, K  Tanaka, H  Makishima, H  Wang, X  Xu, Y  Doisaki, S  Hama, A  Nakanishi, K  Takahashi, Y  Yoshida, N  Maciejewski, JP  Miyano, S  Ogawa, S  Kojima, S 
Citation: Sakaguchi H, etal., Nat Genet. 2013 Aug;45(8):937-41. doi: 10.1038/ng.2698. Epub 2013 Jul 7.
Pubmed: (View Article at PubMed) PMID:23832011
DOI: Full-text: DOI:10.1038/ng.2698

Juvenile myelomonocytic leukemia (JMML) is an intractable pediatric leukemia with poor prognosis whose molecular pathogenesis is poorly understood, except for somatic or germline mutations of RAS pathway genes, including PTPN11, NF1, NRAS, KRAS and CBL, in the majority of cases. To obtain a complete registry of gene mutations in JMML, whole-exome sequencing was performed for paired tumor-normal DNA from 13 individuals with JMML (cases), which was followed by deep sequencing of 8 target genes in 92 tumor samples. JMML was characterized by a paucity of gene mutations (0.85 non-silent mutations per sample) with somatic or germline RAS pathway involvement in 82 cases (89%). The SETBP1 and JAK3 genes were among common targets for secondary mutations. Mutations in the latter were often subclonal and may be involved in the progression rather than the initiation of leukemia, and these mutations associated with poor clinical outcome. Our findings provide new insights into the pathogenesis and progression of JMML.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
CRRD Object Information
CRRD ID: 11069125
Created: 2016-04-27
Species: All species
Last Modified: 2016-04-27
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.